LGD-4033 (Ligandrol) is a novel non-steroidal oral SARM that binds to AR with high affinity (Ki of ~1 nM) and selectivity. It’s in a class of androgen receptor (AR) ligands that is tissue selective, Entwickelt zur Behandlung von krebsbedingtem Muskelschwund, akute und chronische Erkrankungen und altersbedingter Muskelschwund. LGD-4033 (Ligandrol) is expected to produce the therapeutic benefits of …